ATE205881T1 - Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen - Google Patents

Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Info

Publication number
ATE205881T1
ATE205881T1 AT97935646T AT97935646T ATE205881T1 AT E205881 T1 ATE205881 T1 AT E205881T1 AT 97935646 T AT97935646 T AT 97935646T AT 97935646 T AT97935646 T AT 97935646T AT E205881 T1 ATE205881 T1 AT E205881T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
infections caused
composition against
against tumors
papilloma viruses
Prior art date
Application number
AT97935646T
Other languages
German (de)
English (en)
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205881(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE205881T1 publication Critical patent/ATE205881T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97935646T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen ATE205881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (1)

Publication Number Publication Date
ATE205881T1 true ATE205881T1 (de) 2001-10-15

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97935646T ATE205881T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
AT01109013T ATE265535T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01109013T ATE265535T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (https=)
JP (2) JP4070815B2 (https=)
AT (2) ATE205881T1 (https=)
AU (1) AU736720B2 (https=)
CA (1) CA2234263C (https=)
DE (2) DE69706825T3 (https=)
DK (2) DK1149910T3 (https=)
ES (2) ES2215805T3 (https=)
FR (1) FR2751879B1 (https=)
HK (1) HK1043809B (https=)
PT (2) PT862634E (https=)
WO (1) WO1998004705A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1089758A1 (fr) * 1998-06-26 2001-04-11 Aventis Pasteur Immunisation a ciblage mucosal
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
IN2012DN01577A (https=) 2009-07-21 2015-06-05 Transgene Sa
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0451550A3 (en) † 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ES2194839T3 (es) * 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU712714B2 (en) * 1994-10-03 1999-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
EP1149910A1 (fr) 2001-10-31
HK1043809A1 (en) 2002-09-27
EP0862634B1 (fr) 2001-09-19
DK0862634T4 (da) 2006-05-08
WO1998004705A1 (fr) 1998-02-05
DK1149910T3 (da) 2004-08-02
ATE265535T1 (de) 2004-05-15
EP1149910B1 (fr) 2004-04-28
ES2215805T3 (es) 2004-10-16
EP0862634A1 (fr) 1998-09-09
CA2234263A1 (fr) 1998-02-05
CA2234263C (fr) 2009-10-13
DK0862634T3 (da) 2002-01-21
JP2000500662A (ja) 2000-01-25
JP2007254474A (ja) 2007-10-04
AU736720B2 (en) 2001-08-02
ES2163795T5 (es) 2006-07-16
HK1043809B (zh) 2004-12-03
FR2751879A1 (fr) 1998-02-06
JP4070815B2 (ja) 2008-04-02
DE69706825T2 (de) 2002-05-02
AU3855297A (en) 1998-02-20
ES2163795T3 (es) 2002-02-01
PT1149910E (pt) 2004-09-30
DE69706825D1 (de) 2001-10-25
FR2751879B1 (fr) 1998-10-30
DE69728914D1 (de) 2004-06-03
EP0862634B2 (fr) 2006-03-01
DE69728914T2 (de) 2005-04-07
JP4198735B2 (ja) 2008-12-17
PT862634E (pt) 2002-03-28
DE69706825T3 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
PT696326E (pt) Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
ATE221059T1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
ATE108437T1 (de) Substituierte diaminophthalimide und analoga.
ATE169637T1 (de) Derivate des dolastatin
BR1100143A (pt) Composto, e, composição farmacêutica.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0862634

Country of ref document: EP